Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Posted by on Sep 12th, 2026

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eighteen analysts that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $147.1333.

Several brokerages have issued reports on PTGX. Wall Street Zen upgraded Protagonist Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 22nd. Wolfe Research reiterated an “outperform” rating on shares of Protagonist Therapeutics in a report on Monday, August 31st. Wedbush boosted their price target on shares of Protagonist Therapeutics from $118.00 to $173.00 and gave the company an “outperform” rating in a research report on Monday, August 10th. Truist Financial upped their price objective on shares of Protagonist Therapeutics from $145.00 to $170.00 and gave the company a “buy” rating in a report on Monday, August 10th. Finally, The Goldman Sachs Group raised shares of Protagonist Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $110.00 to $186.00 in a research note on Monday, August 10th.

Read Our Latest Stock Analysis on PTGX

Insider Activity at Protagonist Therapeutics

In related news, CEO Dinesh V. Ph D. Patel sold 7,278 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $144.10, for a total transaction of $1,048,759.80. Following the sale, the chief executive officer directly owned 522,968 shares of the company’s stock, valued at $75,359,688.80. This represents a 1.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William D. Waddill sold 9,000 shares of Protagonist Therapeutics stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $117.94, for a total transaction of $1,061,460.00. Following the sale, the director directly owned 7,825 shares of the company’s stock, valued at approximately $922,880.50. This trade represents a 53.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 234,000 shares of company stock worth $34,192,827. Corporate insiders own 5.19% of the company’s stock.

Institutional Trading of Protagonist Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of Protagonist Therapeutics in the second quarter valued at about $1,263,535,000. California State Teachers Retirement System increased its position in shares of Protagonist Therapeutics by 12,217.3% in the second quarter. California State Teachers Retirement System now owns 7,227,439 shares of the company’s stock worth $885,939,000 after acquiring an additional 7,168,762 shares in the last quarter. State Street Corp grew its holdings in Protagonist Therapeutics by 18.5% during the 2nd quarter. State Street Corp now owns 3,207,543 shares of the company’s stock valued at $177,281,000 after purchasing an additional 500,924 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Protagonist Therapeutics by 66.2% during the fourth quarter. Wellington Management Group LLP now owns 3,171,423 shares of the company’s stock worth $276,992,000 after acquiring an additional 1,262,977 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in Protagonist Therapeutics by 9.1% in the first quarter. Janus Henderson Group PLC now owns 2,891,527 shares of the company’s stock valued at $304,866,000 after purchasing an additional 241,546 shares during the last quarter. 98.63% of the stock is owned by hedge funds and other institutional investors.

Protagonist Therapeutics Trading Up 2.1%

PTGX opened at $148.18 on Monday. Protagonist Therapeutics has a twelve month low of $57.90 and a twelve month high of $160.81. The firm has a market capitalization of $9.59 billion, a PE ratio of 143.87 and a beta of 1.80. The firm’s 50-day moving average price is $143.14 and its 200 day moving average price is $116.95.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $2.29 earnings per share for the quarter, topping analysts’ consensus estimates of $2.27 by $0.02. The business had revenue of $213.47 million for the quarter, compared to analyst estimates of $212.03 million. Protagonist Therapeutics had a net margin of 29.40% and a return on equity of 12.03%. The firm’s revenue for the quarter was up 3746.8% compared to the same quarter last year. As a group, analysts predict that Protagonist Therapeutics will post 4.22 earnings per share for the current fiscal year.

About Protagonist Therapeutics

(Get Free Report)

Protagonist Therapeutics, Inc is a biopharmaceutical company focused on developing peptide-based medicines for immune-mediated diseases and hematologic disorders. The company uses its peptide discovery and development platform to create therapies designed to selectively modulate disease-related biological pathways.

Protagonist’s pipeline has included icotrokinra (also known as JNJ-2113), an oral peptide that targets the interleukin-23 receptor and is being developed for inflammatory and immune-mediated conditions in collaboration with Johnson & Johnson.

Featured Stories

Analyst Recommendations for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.